- Home
- NXRT vs MDXG Comparison
NXRT vs MDXG Comparison
Compare NXRT & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXRT | MDXG |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.1M | 1.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NXRT | MDXG |
|---|---|---|
| Price | $28.14 | $7.05 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $36.33 | $11.00 |
| AVG Volume (30 Days) | 171.2K | ★ 773.5K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | ★ 7.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | $253,196,000.00 | ★ $393,442,000.00 |
| Revenue This Year | N/A | $19.13 |
| Revenue Next Year | $2.45 | $2.11 |
| P/E Ratio | ★ N/A | $26.84 |
| Revenue Growth | N/A | ★ 14.77 |
| 52 Week Low | $27.92 | $5.79 |
| 52 Week High | $45.19 | $9.71 |
Technical Indicators
Market Signals| Indicator | NXRT | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 50.25 |
| Support Level | $27.92 | $6.62 |
| Resistance Level | $29.25 | $7.45 |
| Average True Range (ATR) | 0.81 | 0.25 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 11.10 | 51.52 |
Price Performance
Historical ComparisonAbout NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.